Minocycline 200 mg or 400 mg versus placebo for mild Alzheimer’s disease: the MADE Phase II, three-arm RCT

Minocycline 200 mg or 400 mg versus placebo for mild Alzheimer’s disease: the MADE Phase II, three-arm RCT

Background: Minocycline is an anti-inflammatory drug and protects against the toxic effects of β-amyloid in vitro and in animal models of Alzheimer’s disease. To the best of our knowledge, no randomised placebo-controlled clinical trials in patients with Alzheimer’s disease looking at the efficacy a...

Full description

Bibliographic Details
Main Authors: Robert Howard, Olga Zubko, Richard Gray, Rosie Bradley, Emma Harper, Linda Kelly, Lynn Pank, John O’Brien, Chris Fox, Naji Tabet, Gill Livingston, Peter Bentham, Rupert McShane, Alistair Burns, Craig Ritchie, Suzanne Reeves, Simon Lovestone, Clive Ballard, Wendy Noble, Gordon Wilcock, Ramin Nilforooshan
Format: Article
Language:English
Published: NIHR Journals Library 2020-04-01
Series:Efficacy and Mechanism Evaluation
Subjects:
humans
minocycline
dizziness
activities of daily living
intention-to-treat analysis
amyloidogenic proteins
alzheimer disease
vertigo
amyloidosis
models, animal
outcome assessment (health care)
mental status and dementia tests
cognition
Online Access:https://doi.org/10.3310/eme07020

Internet

https://doi.org/10.3310/eme07020

Similar Items